ERBB2 and breast carcinoma: A negative correlation was recognized between circulating miRNA-21 and overall survival in HER2-positive breast cancers treated with neoadjuvant chemotherapy and trastuzumab or lapatinib (Amirfallahet al. 2021; Feng and Tsao 2016; Özgün et al. 2013).